Neuroendocrine Tumors, Version 1.2015

Kulke, Matthew H.; Shah, Manisha H.; Benson, Al B.; Bergsland, Emily K.; Berlin, Jordan; Blaszkowsky, Lawrence S.; Emerson, Lyska L.; Engstrom, Paul F.; Fanta, Paul T.; Giordano, Thomas J.; Goldner, Whitney; Halfdanarson, Thorvardur R.; Heslin, Martin J.; Kandeel, Fouad; Kunz, Pamela L.; Kuvshinoff, Boris W.; Lieu, Christopher H.; Moley, Jeffrey F.; Munene, Gitonga; Pillarisetty, Venu G.; Saltz, Leonard B.; Sosa, Julie Ann; Strosberg, Jonathan R.; Vauthey, Jean Nicolas; Wolfgang, Christopher L.; Yao, James C.; Burns, Joseph E.; Freedman-Cass, Deborah A.

doi:10.6004/jnccn.2015.0011

Cited by 317 publications

(280 citation statements)

References 62 publications

Supporting

Mentioning

269

Contrasting

Unclassified

Order By: Relevance

“…However, the mentioned papers do not provide a real picture of clinical practice, where what is actually required is to distinguish NENs from non-neuroendocrine malignancies posing to clinicians issues of differential diagnosis. This is particularly crucial for non-functional NENs, given the absence of the distinctive clinical and biochemical features related to hormone overproduction (Kulke et al 2015). To date, poor data are available about this issue.…”

Section: Oncological Causes Of Cga Elevationmentioning

confidence: 99%

Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame

Marotta

Zatelli

Sciammarella³

et al. 2018

Endocrine-Related Cancer

128

104

View full text Add to dashboard Cite

Owing to the heterogeneity of neuroendocrine neoplasms (NENs), the availability of reliable circulating markers is critical for improving diagnostics, prognostic stratification, follow-up and definition of treatment strategy. This review is focused on chromogranin A (CgA), a hydrophilic glycoprotein present in large dense core vesicles of neuroendocrine cells. Despite being long identified as the most useful NEN-related circulating marker, clinical application of CgA is controversial. CgA assays still lack standardization, thus hampering not only clinical management but also the comparison between different analyses. In the diagnostic setting, clinical utility of CgA is limited as hampered by (a) the variety of oncological and non-oncological conditions affecting marker levels, which impairs specificity; (b) the fact that 30-50% of NENs show normal CgA, which impairs sensitivity. Regarding the prognostic phase, there is prospective evidence which demonstrates that advanced NENs secreting CgA have poorer outcome, as compared with those showing non-elevated marker levels. Although the identification of cut-offs allowing a proper risk stratification of CgA-secreting patients has not been performed, this represents the most important clinical application of the marker. By contrast, based on prospective studies, the trend of elevated circulating CgA does not represent a valid indicator of morphological evolution and has therefore no utility for the follow-up phase. Ultimately, current knowledge about the role of the marker for the definition of treatment strategy is poor and is limited by the small number of available studies, their prevalent retrospective nature and the absence of control groups of untreated subjects.

show abstract

Section: Oncological Causes Of Cga Elevationmentioning

confidence: 99%

Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame

Marotta

Zatelli

Sciammarella³

et al. 2018

Endocrine-Related Cancer

128

104

View full text Add to dashboard Cite

show abstract

“…They represent 8.7% of all gastrointestinal neuroendocrine tumors, and account for 0.6-2% of all gastric polyps identified (5,6). GNETs are classified into four types, based on pathogenesis and histomorphologic characteristics; these types differ in biological behavior and prognosis, ranging from benign to high- metastasized (6,7). In the present case, the primary symptom was gastrointestinal bleeding and we successfully managed the tumor by endoscopic submucosal dissection.…”

Section: Discussionmentioning

confidence: 76%

“…Periodical follow-up is recommended as recurrence may be encountered. ly malignant biological behavior and extremely poor prognosis (7). Preoperative diagnosis of GNETs remains difficult because of their rarity of occurrence, protean clinical manifestations, and wide variety of radiological and endoscopic presentation.…”

Section: Discussionmentioning

confidence: 99%

Gastric neuroendocrine tumor presenting with gastrointestinal bleeding

et al. 2015

View full text Add to dashboard Cite

“…The National Comprehensive Cancer Network recommends the use of cisplatin or carboplatin and etoposide (10,11). Currently, prognosis remains poor, with a median survival of 7 to 10 months (12).…”

Section: Discussionmentioning

confidence: 99%

A Rare Type of Colorectal Cancer: Mixed Adeno-Neuroendocrine Carcinoma (MANEC)

Cherbanyk¹,

Gassend²,

Dimitrief³

et al. 2017

chr

View full text Add to dashboard Cite

RezumatScopul acestei lucrări este de a raporta datele clinico-patologice aferente unui caz de adenocarcinom neuroendocrin mixt metastatic (MANEC) cecal; mai puţin de zece astfel de cazuri au fost descrise în literatura de specialitate britanică. Un pacient în vârstă de 57 de ani s-a prezentat cu un adenocarcinom neuroendocrin mixt metastatic (MANEC) cecal cu determinări secundare hepatice şi carcinomatoză peritoneală. S-au efectuat hemicolectomie dreaptă şi omentectomie de urgenţă, urmate de mai multe cicluri de chimioterapie paliativă cu rezultate slabe. Progresia metastatică a continuat, iar pacientul a decedat la 10 luni de la prezentarea la Camera de Gardă. MANEC sunt definite ca formaţiuni alcătuite din minimum 30% componentă neuroendocrină şi minimum 30% din cea adenocarcinomatoasă. Localizarea tumorii, precum şi proporţiile şi comportamentul celor două componente ale sale influenţează tratamentul. Totuşi, ghidurile de chimioterapie rămân slab definite, iar prognosticul rămâne unul sumbru, cu supravieţuirea medie sub un an de zile. AbstractThe aim of this paper is to report the clinicopathological data of one case of mixed metastatic adenoneuroendocrine carcinoma (MANEC) in the caecum; less than ten cases of which have been described in the English literature. A 57-year-old male patient presented with a mixed adenoneuroendocrine carcinoma (MANEC) of the caecum with liver metastasis and peritoneal carcinomatosis. An emergency right hemicolectomy and omentectomy were performed, followed by several cycles of unsuccessful palliative chemotherapy. The metastasis developed further, and the patient died 10 months after presenting to the emergency room. MANECs are defined as containing at least 30% of both a neuroendocrine and an adenocarcinomatous component. The location of the tumour and the proportions and behaviour of its two components influence the treatment. However, chemotherapy guidelines remain poorly defined, and prognosis remains sombre, with median survival of less than one year.

show abstract

Neuroendocrine Tumors, Version 1.2015

Cited by 317 publications

References 62 publications

Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame

Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame

Gastric neuroendocrine tumor presenting with gastrointestinal bleeding

A Rare Type of Colorectal Cancer: Mixed Adeno-Neuroendocrine Carcinoma (MANEC)

Contact Info

Product

Resources

About